Last year, National Jewish Health was named the #1 respiratory hospital by U.S. News & World Report, followed by Mayo Clinic, Cleveland Clinic and Mass General. This is the 16th year we have achieved that recognition. The hospital’s physicians and scientists are proud of this recognition, and are grateful for the support of individuals, businesses and foundations from coast to coast that enable us to continue exploring big ideas that will change the way some of the world’s most challenging diseases are treated.
Chronic Obstructive Pulmonary Disease (COPD)
National Jewish Health is committed to stopping the progression of COPD and reversing the disease’s damage to the lungs. For several years now, Dr. James Crapo has been leading the largest study of COPD ever with more than 10,000 patients. His team’s work is geared toward discovering what genetic factors contribute to developing COPD and the treatments that can target those factors. Dr. Irina Petrache, Chief of The Tuchman Family Division of Pulmonary, Critical Care and Sleep Medicine, is also working on several studies, including looking for non-antibiotic approaches to reducing COPD exacerbations. It’s because of this research and our commitment to collaborative, personalized care that U.S. News & World Report
named our care for COPD patients as high performing, the best rating available.
We are also working to cure severe asthma. Twenty-five million people in this country suffer from asthma and half of them do not have their disease under control. Asthma is still responsible for more school and work days lost than any other condition. Through the Cohen Family Asthma Institute, we are on the way to understanding what triggers severe asthma attacks and finding ways to prevent them.
We also have a goal to prevent childhood allergies, another major problem in this country. This work is being done in the Silverstein Family Department of Pediatrics. Hundreds of thousands of children suffer from the allergic march that starts with eczema, goes to food allergies and then asthma. We have been leaders in the research and treatment of allergic diseases since 1967, when we identified the molecule responsible for immune response. As a result of this discovery, allergy medications have been developed, benefiting hundreds of millions of people around the world.
Interstitial Lung Disease (ILD)
Oftentimes characterized by shortness of breath and coughing that can lead to respiratory failure, the more than 130 maladies that fall under the ILD umbrella are challenging to diagnose and can go undetected or misdiagnosed for years. National Jewish Health is well-positioned to take ILD clinical and research efforts to the next level. In fact, the National Institutes of Health has designated National Jewish Health as a Specialized Center of Research for ILD. Together, our basic scientists, doctors and staff are broadening their understanding of the causes of ILD and developing new treatment approaches. They want to understand the mechanisms of scarring in ILD and are conducting extensive research in this area.
This is just a sample of the big challenges that National Jewish Health is tackling to improve the lives of children and adults with some of the most complex conditions we face. As we strive toward big discoveries with big impact, we never lose sight of what is most important: saving and improving lives through a model of care that is collaborative, compassionate and precise. Your support of the Breath of Life Golf Classic over the past 21 years has enabled us to continue this work.